Benzinga
Benzinga
Notizie dall’Italia
Azioni
Indici
Obbligazioni
ETF
Economia
Generale
Notizie USA
Azioni
Indici
Utili
Notizie Economiche
Mercati di previsione
Mercati privati
Altri Mercati
Dicono gli Analisti
Trading
Comunicati stampa
Notizie internazionali
Europa
Asia
Criptovalute
Notizie
Altcoin
Bitcoin
Blockchain
Dogecoin
Ethereum
Shiba Inu
NFT
Finanza personale
Investire in criptovalute
Investire in azioni
Forex
Benzinga
mercoledì, ottobre 28
Notizie dall’Italia
Azioni
Indici
Obbligazioni
ETF
Economia
Generale
Notizie USA
Azioni
Indici
Utili
Notizie Economiche
Mercati di previsione
Mercati privati
Altri Mercati
Dicono gli Analisti
Trading
Comunicati stampa
Notizie internazionali
Europa
Asia
Criptovalute
Notizie
Altcoin
Bitcoin
Blockchain
Dogecoin
Ethereum
Shiba Inu
NFT
Finanza personale
Investire in criptovalute
Investire in azioni
Forex
Aardvark Therapeutics Inc
AARD
NASDAQ
Watchlist
Get Report
Trade with Public
Get Report
Trade with Public
$1.30
0.22
20.37%
Ult. Agg.: Oct 27, 7:58 PM
Get Report
Panoramica
Notizie
Previsioni utili
Eventi
Obiettivi di prezzo
Dati finanziari
Sentiment
Azionariato
Confronta
Opzioni
Rapporto azionario
PRO
Perché si muove?:
Aardvark Therapeutics shares are trading lower after HC Wainwright & Co. lo...
Aardvark Therapeutics Financials
Aardvark Therapeutics (AARD) financial statements — income, revenue, gross margin and key metrics.
Earnings & Guidance News
PRO
Aardvark Therapeutics Q2 EPS $(0.66) Beats $(0.91) Estimate
Aardvark Therapeutics (NASDAQ:AARD) reported quarterly losses of $(0.66) per share which beat the analyst consensus estimate of $(0.91) by 27.47 percent. This is unchanged from the same period last year.
Benzinga Newsdesk
PRO
Aardvark Therapeutics Q1 EPS $(0.99) Misses $(0.90) Estimate
Aardvark Therapeutics (NASDAQ:AARD) reported quarterly losses of $(0.99) per share which missed the analyst consensus estimate of $(0.90) by 10 percent. This is a 39.44 percent decrease over losses of $(0.71) per share
Benzinga Newsdesk
PRO
Aardvark Therapeutics Q4 EPS $(0.81) Beats $(0.91) Estimate
Aardvark Therapeutics (NASDAQ:AARD) reported quarterly losses of $(0.81) per share which beat the analyst consensus estimate of $(0.91) by 11.09 percent. This is a 62.5 percent increase over losses of $(2.16) per share
Benzinga Newsdesk
Stock Market Today: S&P 500, Dow Jones Futures Slide Amid War Against Iran— AMTD Digital, Aardvark, MongoDB In Focus
U.S. stock futures fell sharply on Monday following Friday’s losses. Futures of the major benchmark indices were negative amid the ongoing Iran-U.S. conflict.
Rishabh Mishra
PRO
Aardvark Therapeutics Q3 EPS $(0.75) Beats $(0.80) Estimate
Aardvark Therapeutics (NASDAQ:AARD) reported quarterly losses of $(0.75) per share which beat the analyst consensus estimate of $(0.80) by 6.72 percent. This is a 28.57 percent increase over losses of $(1.05) per share
Benzinga Newsdesk
PRO
Aardvark Therapeutics Q2 EPS $(0.66) Misses $(0.61) Estimate
Aardvark Therapeutics (NASDAQ:AARD) reported quarterly losses of $(0.66) per share which missed the analyst consensus estimate of $(0.61) by 7.67 percent. This is a 51.82 percent increase over losses of $(1.37) per share
Benzinga Newsdesk
